$BOLT News Article - Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 | Benzinga
https://marketwirenews.com/news-releases/bolt...62822.html